Cargando…
Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting
INTRODUCTION: Studies on treatment adherence to glucose‐lowering drugs among patients with type 2 diabetes (T2D) including concomitant treatment for other cardiovascular risk factors are scarce. We aimed to estimate the prevalence of good adherence to all medications used to control diabetes, hypert...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917867/ https://www.ncbi.nlm.nih.gov/pubmed/34964310 http://dx.doi.org/10.1002/edm2.320 |
_version_ | 1784668639160434688 |
---|---|
author | Orozco‐Beltrán, Domingo Cinza‐Sanjurjo, Sergio Escribano‐Serrano, José López‐Simarro, Flora Fernández, Gonzalo Gómez García, Antón Ferreira de Campos, Karine Cedenilla Horcajuelo, Marta |
author_facet | Orozco‐Beltrán, Domingo Cinza‐Sanjurjo, Sergio Escribano‐Serrano, José López‐Simarro, Flora Fernández, Gonzalo Gómez García, Antón Ferreira de Campos, Karine Cedenilla Horcajuelo, Marta |
author_sort | Orozco‐Beltrán, Domingo |
collection | PubMed |
description | INTRODUCTION: Studies on treatment adherence to glucose‐lowering drugs among patients with type 2 diabetes (T2D) including concomitant treatment for other cardiovascular risk factors are scarce. We aimed to estimate the prevalence of good adherence to all medications used to control diabetes, hypertension and dyslipidemia and to analyse cardiometabolic control and its associated factors in T2D patients in the primary care (PC) setting. METHODS: Observational, retrospective study conducted in adult patients with T2D who were followed in the PC setting in Spain. Patients were classified as adherent in a particular category if the summary of the proportion of days covered (PDC) for a particular medication category was ≥80% and were considered globally adherent if the PDC was ≥80% for each of the 3 medication categories. RESULTS: A total of 457 evaluable patients were recruited, among which 321 patients (70.3%, 95% CI 65.8 to 74.4) were adherent to the three drug categories. The proportion of patients controlled for the 3 cardiometabolic risk factors was 31% according to the contemporary clinical practice guideline criteria, 58% according to investigator judgment and 36% when the objective for HbA1c was individualized. In a multivariate analysis, presenting comorbidities was associated with a lower likelihood of showing adequate control of dyslipidemia (odds ratio [OR] 0.25, 95% CI, 0.16–0.40) and the three cardiometabolic factors as a whole (OR 0.43, 95% CI 0.26–0.70). In a post hoc analysis, therapeutic inertia was found to be greater for dyslipidemia and hypertension than for T2D. CONCLUSIONS: Despite a relatively high adherence to all medications for treating diabetes, hypertension and dyslipidemia in patients with T2D in the PC setting in Spain, the control of cardiometabolic risk factors as a whole is far from optimal. This could be related, at least in part, to the high frequency of comorbidity of these patients. |
format | Online Article Text |
id | pubmed-8917867 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89178672022-03-18 Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting Orozco‐Beltrán, Domingo Cinza‐Sanjurjo, Sergio Escribano‐Serrano, José López‐Simarro, Flora Fernández, Gonzalo Gómez García, Antón Ferreira de Campos, Karine Cedenilla Horcajuelo, Marta Endocrinol Diabetes Metab Original Research Articles INTRODUCTION: Studies on treatment adherence to glucose‐lowering drugs among patients with type 2 diabetes (T2D) including concomitant treatment for other cardiovascular risk factors are scarce. We aimed to estimate the prevalence of good adherence to all medications used to control diabetes, hypertension and dyslipidemia and to analyse cardiometabolic control and its associated factors in T2D patients in the primary care (PC) setting. METHODS: Observational, retrospective study conducted in adult patients with T2D who were followed in the PC setting in Spain. Patients were classified as adherent in a particular category if the summary of the proportion of days covered (PDC) for a particular medication category was ≥80% and were considered globally adherent if the PDC was ≥80% for each of the 3 medication categories. RESULTS: A total of 457 evaluable patients were recruited, among which 321 patients (70.3%, 95% CI 65.8 to 74.4) were adherent to the three drug categories. The proportion of patients controlled for the 3 cardiometabolic risk factors was 31% according to the contemporary clinical practice guideline criteria, 58% according to investigator judgment and 36% when the objective for HbA1c was individualized. In a multivariate analysis, presenting comorbidities was associated with a lower likelihood of showing adequate control of dyslipidemia (odds ratio [OR] 0.25, 95% CI, 0.16–0.40) and the three cardiometabolic factors as a whole (OR 0.43, 95% CI 0.26–0.70). In a post hoc analysis, therapeutic inertia was found to be greater for dyslipidemia and hypertension than for T2D. CONCLUSIONS: Despite a relatively high adherence to all medications for treating diabetes, hypertension and dyslipidemia in patients with T2D in the PC setting in Spain, the control of cardiometabolic risk factors as a whole is far from optimal. This could be related, at least in part, to the high frequency of comorbidity of these patients. John Wiley and Sons Inc. 2021-12-28 /pmc/articles/PMC8917867/ /pubmed/34964310 http://dx.doi.org/10.1002/edm2.320 Text en © 2021 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Articles Orozco‐Beltrán, Domingo Cinza‐Sanjurjo, Sergio Escribano‐Serrano, José López‐Simarro, Flora Fernández, Gonzalo Gómez García, Antón Ferreira de Campos, Karine Cedenilla Horcajuelo, Marta Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting |
title | Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting |
title_full | Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting |
title_fullStr | Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting |
title_full_unstemmed | Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting |
title_short | Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting |
title_sort | adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917867/ https://www.ncbi.nlm.nih.gov/pubmed/34964310 http://dx.doi.org/10.1002/edm2.320 |
work_keys_str_mv | AT orozcobeltrandomingo adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting AT cinzasanjurjosergio adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting AT escribanoserranojose adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting AT lopezsimarroflora adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting AT fernandezgonzalo adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting AT gomezgarciaanton adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting AT ferreiradecamposkarine adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting AT cedenillahorcajuelomarta adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting |